natgillin/translations-raw huggingface dataset:
Symptoms of overdose may include headache, nausea, vomiting, fast heart rate, warmth or tingling, or feeling like you might pass out (feeling faint/dizziness). 
Med simptomi prevelikega odmerjanja so lahko glavobol, slabost, bruhanje, hitro bitje srca, občutek toplote ali mravljinčenja ali občutek, da boste omedleli (omedlevica/omotica).
Reconstitution and dilution should be carried out immediately prior to use. 
Pripravo in razredčenje je treba opraviti tik pred uporabo.
Flolan is indicated for the treatment of pulmonary arterial hypertension (PAH) (idiopathic or heritable PAH and PAH associated with connective tissue diseases) in patients with WHO Functional Class III-IV symptoms to improve exercise capacity (see section 5.1). 
Zdravilo Flolan je indicirano za zdravljenje pljučne arterijske hipertenzije (PAH) (idiopatske ali dedne PAH in PAH, povezane z vezivnotkivnimi boleznimi) pri bolnikih s simptomi funkcijskega razreda III-IV po Svetovni zdravstveni organizaciji (SZO) za izboljšanje obremenitvene sposobnosti (glejte poglavje 5.1).
The other ingredients are Mannitol, Glycine, Sodium Chloride, Sodium Hydroxide and Water. 
Pomožne snovi so manitol, glicin, natrijev klorid, natrijev hidroksid in voda.
Epoprostenol is the most potent inhibitor of platelet aggregation known. 
Epoprostenol je najmočnejši znani zaviralec agregacije trombocitov.
What Flolan is and what it is used for What you need to know before you take Flolan How to take Flolan 
Kaj je zdravilo Flolan in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Flolan Kako jemati zdravilo Flolan Možni neželeni učinki
• medicines used to treat high blood pressure 
• zdravila za zdravljenje visokega krvnega tlaka,
The half-life for the spontaneous breakdown to 6-oxo-prostaglandin F1 alpha in man is expected to be no more than 6 minutes, and may be as short as 2 to 3 minutes, as estimated from in vitro rates of degradation of epoprostenol in human whole blood. 
Pričakovani razpolovni čas spontane razgradnje v 6-okso-prostaglandin F1 alfa pri človeku ne presega 6 minut in je morda celo samo od 2 do 3 minute, če ocenjujemo glede na hitrost razgradnje epoprostenola v človeški polni krvi in vitro.
Thus, therapy with Flolan requires commitment by the patient to sterile drug reconstitution, drug administration, care of the permanent central venous catheter, and access to intense and ongoing patient education. 
Zato zdravljenje z zdravilom Flolan zahteva, da bolnik skrbi za sterilno pripravo in dajanje zdravila, oskrbo stalnega centralnega venskega katetra ter možnost intenzivnega in stalnega izobraževanja.
At week 12, NYHA functional class improved in 21 of 51 (41%) patients treated with epoprostenol compared to none of the 48 patients treated with conventional therapy alone. 
Po 12 tednih se je funkcijski razred po NYHA izboljšal pri 21 od 51 (41 %) bolnikov, zdravljenih z epoprostenolom, in pri nobenem od 48 bolnikov, ki so prejemali samo konvencionalno zdravljenje.
An abrupt interruption of therapy can induce a rebound of pulmonary arterial hypertension resulting in dizziness, asthenia, increase dyspnoea, and may lead to death (see section 4.2). 
Nenadna prekinitev zdravljenja lahko povzroči preobratno pljučno arterijsko hipertenzijo s posledično omotico, astenijo, poslabšanjem dispneje ter lahko povzroči smrt (glejte poglavje 4.2).
If you take more Flolan than you should 
Če ste vzeli večji odmerek zdravila Flolan, kot bi smeli
You will start with an infusion of Flolan. 
Zdravljenje boste začeli z infuzijo zdravila Flolan.
Your dose may need to be reduced or your infusion stopped. 
Morda vam bo moral zmanjšati odmerek ali prekiniti infundiranje zdravila.
However, the reverse was observed for postdialysis days with epoprostenol (N=1/5) compared to heparin (N=8/16). 
Obratno pa je bilo ugotovljeno za dneve po dializi z epoprostenolom (n = 1/5) v primerjavi s heparinom (n = 8/16).
It is unknown if epoprostenol or its metabolites are excreted in human milk. 
Ni znano, ali se epoprostenol ali njegovi presnovki pri človeku izločajo v materino mleko.
PHARMACEUTICAL FORM Powder for concentrate for solution for infusion: - White or off-white freeze dried powder Solvent for parenteral use: - Clear, colourless solution (pH 10.3 - 10.8) 
FARMACEVTSKA OBLIKA Prašek za koncentrat za raztopino za infundiranje: - bel ali skoraj bel liofiliziran prašek Vehikel za parenteralno uporabo: - bistra, brezbarvna raztopina (pH 10,3-10,8)
Pain at the injection site*, chest pain 
Pogosti bolečine na mestu injiciranja*, bolečina v prsih
Independent of technical difficulties which occurred rarely with either treatment, major dialysis-limiting clotting did not occur in 93% of all epoprostenol dialyses and 99% of all heparin dialyses. 
Neupoštevaje tehnične težave (ki so bile pri obeh načinih zdravljenja redke) se pomembno strjevanje, ki bi omejilo dializo, ni pojavilo pri 93 % vseh dializ z epoprostenolom in pri 99 % vseh dializ s heparinom.
• feeling tired, weak 
• utrujenost, šibkost.
For further instructions on reconstitution and dilution of the medicinal product before administration, (see section 6.6). 
Za dodatna navodila o pripravi in razredčenju zdravila pred uporabo glejte poglavje 6.6.
Dry mouth 
Občasni suha usta
During long-term infusion, the occurrence of dose-related pharmacological events similar to those observed during the dose-ranging period may necessitate a decrease in infusion rate, but the adverse reactions may occasionally resolve without dosage adjustment. 
Med dolgotrajnim infundiranjem se lahko pojavijo z odmerkom povezani farmakološki učinki, podobni tistim med obdobjem ugotavljanja odmerka, in lahko zahtevajo zmanjšanje hitrosti infundiranja, neželeni učinki pa občasno lahko minejo brez prilagajanja odmerka.
However, more patients in both treatment groups (28/51 [55%] with epoprostenol and 35/48 [73%] with conventional therapy alone) showed no change in functional class, and 2/51 (4%) with epoprostenol and 13/48 (27%) with conventional therapy alone worsened. 
Vendar pa se funkcijski razred pri večjem delu bolnikov v obeh terapevtskih skupinah ni spremenil (28/51 [55 %] z epoprostenolom in 35/48 [73 %] s konvencionalnim zdravljenjem samim), pri 2/51 (4 %) z epoprostenolom in 13/48 (27 %) s konvencionalnim zdravljenjem samim pa se je poslabšal.
Flolan is contraindicated in patients: • with known hypersensitivity to the active substance(s) or to any of the excipients listed in section 
Zdravilo Flolan je kontraindicirano pri bolnikih: • z znano preobčutljivostjo na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju
METHOD AND ROUTE(S) OF ADMINISTRATION The powder needs to be reconstituted and diluted before infusion. 
POSTOPEK IN POT(I) UPORABE ZDRAVILA Prašek je treba pred infundiranjem pripraviti in razredčiti.
General Disorders and Administration Site Conditions Very common Pain (unspecified) Common 
Splošne težave in spremembe na mestu aplikacije Zelo pogosti bolečina (neopredeljena)
The infusion rate should be increased by 1 to 2 nanograms/kg/min increments at intervals sufficient to allow assessment of clinical response; these intervals should be of at least 15 min. 
Hitrost infundiranja je treba povečevati po 1 do 2 nanograma/kg/min v presledkih, ki zadoščajo za oceno kliničnega odziva; ti presledki morajo trajati vsaj 15 minut.
Epoprostenol is only indicated for continuous infusion by intravenous route. 
Epoprostenol je indiciran le za stalno intravensko infundiranje.
Visible clotting (not necessitating intervention) was reported in another 31% of epoprostenol dialyses and 5% of heparin dialyses. 
Vidno strjevanje (ki ni zahtevalo ukrepanja) so zabeležili pri dodatnih 31 % dializ z epoprostenolom in 5 % dializ s heparinom.
• pale skin 
• bleda koža,
Common side effects that may show up in blood tests • decrease in the number of blood platelets (cells that help the blood to clot) 
Pogosti neželeni učinki, ki se lahko pokažejo pri preiskavah krvi • zmanjšanje števila krvnih ploščic (trombocitov; to so celice, ki sodelujejo pri strjevanju krvi).
Effects on platelets have been found to disappear within 2 hours of discontinuing the infusion, and haemodynamic changes due to epoprostenol to return to baseline within 10 minutes of termination of 60 minutes infusion at 1 to 16 nanograms/kg/min. 
Ugotovljeno je, da učinki na trombocite izginejo v 2 urah po koncu infundiranja, hemodinamske spremembe zaradi epoprostenola pa se vrnejo na izhodiščne vrednosti v 10 minutah po koncu 60-minutnega infundiranja od 1 do 16 nanogramov/kg/min.
There are no data regarding the effect of Flolan used in renal dialysis on the ability to drive or operate machinery. 
Podatkov o vplivu zdravila Flolan, uporabljenega pri ledvični dializi, na sposobnost vožnje in upravljanja s stroji ni.
Keep container in the outer carton to protect from light. 
Vsebnik shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
Very rare 
Zelo redki bledica
• stomach discomfort or pain 
• nelagodje ali bolečine v želodcu,
Epoprostenol must not be administered as a bolus injection 
Epoprostenola se ne sme dajati v bolusni injekciji.
Flolan is used to prevent blood clotting during kidney dialysis when heparin cannot be used. 
Zdravilo Flolan se uporablja za preprečevanje krvnih strdkov med ledvično dializo, kadar ni mogoče uporabiti heparina.
Reconstitution, dilution and calculation of infusion rate: 
Priprava, razredčenje in izračun hitrosti infundiranja:
Flolan may either decrease or increase heart rate. 
Zdravilo Flolan lahko poveča ali zmanjša srčno frekvenco.
Infusion rate formulae - examples 
Formule - primeri za hitrost infundiranja
If you are being given Flolan using an infusion pump, a ‘cold pouch' may be used to maintain the temperature of the solution. 
Če zdravilo Flolan prejemate z infuzijsko črpalko, lahko za vzdrževanje temperature raztopine uporabite "hladno vrečko".
Stopping Flolan must be done gradually. 
Prenehanje uporabe zdravila Flolan mora biti opravljeno postopoma.
Sodium Hydroxide (for pH adjustment) 
Natrijev hidroksid (za prilagoditev pH)
Preparation of Flolan intravenous injectable solution: 
Priprava raztopine Flolan za intravensko injiciranje:
For administration using a pump capable of delivering small volume constant infusions, suitable aliquots of concentrated solution may be diluted with sterile sodium chloride 0.9% w/v solution. 
Za uporabo s črpalko, ki lahko daje majhno stalno količino infuzije, je treba ustrezne alikvote koncentrirane raztopine razredčiti s sterilno 0,9 % (m/v) raztopino natrijevega klorida.
The decision to administer Flolan for pulmonary arterial hypertension should be based upon the patient's understanding that there is a high likelihood that therapy with Flolan will be needed for prolonged periods, possibly years, and the patient's ability to accept and care for a permanent i.v. 
Odločitev za uporabo zdravila Flolan pri pljučni arterijski hipertenziji mora temeljiti na bolnikovem razumevanju, da bo zdravljenje zelo verjetno potrebno dolgo časa, morda leta, in bolnikovo zmožnostjo, da sprejme in skrbi za stalni intravenski kateter ter infuzijsko črpalko.
Flolan is a potent pulmonary and systemic vasodilator. 
Zdravilo Flolan je močan pljučni in sistemski vazodilatator.
It may be diluted with sodium chloride 0.9% w/v solution, provided a ratio of 6 volumes of sodium chloride 0.9% w/v solution to 1 volume of concentrated solution is not exceeded e.g. 50 mL of concentrated solution further diluted with a maximum of 300 mL sodium chloride 0.9% w/v solution. 
Razredčiti jo je mogoče z 0,9 % (m/v) raztopino natrijevega klorida, pod pogojem, da ni preseženo razmerje 6 delov 0,9 % (m/v) raztopine natrijevega klorida na 1 del koncentrirane raztopine, npr. 50 ml koncentrirane raztopine, nadalje razredčene z največ 300 ml 0,9 % (m/v) raztopine natrijevega klorida.
Intravenous epoprostenol infusions of up to 15 minutes have been found to produce dose-related increases in cardiac index (CI) and stroke volume (SV), and dose-related decreases in pulmonary vascular resistance (PVR), total pulmonary resistance (TPR) and mean systemic arterial pressure (SAPm). 
Do 15-minutno intravensko infundiranje epoprostenola povzroči od odmerka odvisno povečanje srčnega indeksa (CI - cardiac index) in utripnega volumna (SV - stroke volume) ter od odmerka odvisno zmanjšanje pljučnega žilnega upora (PVR - pulmonary vascular resistance), celotnega pljučnega upora (TPR - total pulmonary resistance) in srednjega sistemskega arterijskega tlaka (SAPm - mean systemic arterial pressure).
Flolan widens the blood vessels to lower the blood pressure in the lungs. 
Zdravilo Flolan razširi žile in tako zniža krvni tlak v pljučih.
Freshly prepared epoprostenol solutions for the treatment of pulmonary arterial hypertension should be used within 12 hours at 25°C, or stored for up to 40 hours at between 2 to 8°C and then used within 8 hours at 
Sveže pripravljeno raztopino epoprostenola za zdravljenje pljučne arterijske hipertenzije je treba uporabiti v 12 urah pri temperaturi 25 °C, lahko pa se jo do 40 ur hrani pri temperaturi od 2 do 8 °C in nato uporabi v 8 urah pri temperaturi 25 °C.
Sodium Hydroxide (for pH adjustment) Water for Injection 
Natrijev hidroksid (za prilagoditev pH) Voda za injekcije
If you have been fitted with a ‘line' into a vein it is very important to keep this area clean, otherwise you could get an infection. 
Zato je zelo pomembno, da ohranjate to mesto čisto, ker se vam sicer lahko pojavi okužba.
Skin damage at the injection site 
Poškodba kože na mestu injiciranja
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Solvent for parenteral use for Flolan 
IME ZDRAVILA IN POT(I) UPORABE Vehikel za parenteralno uporabo za zdravilo Flolan intravenska uporaba
Reconstituted solutions, prepared in real time, must not be administered over more than 12 hours when they are used at room temperature (between 15°C and 25°C). 
Pripravljene raztopine, pripravljene v realnem času, se ne sme dajati več kot 12 ur, če je uporabljena pri sobni temperaturi (med 15 in 25 °C).
This SmPC, labelling and package leaflet is the version valid at the time of Commission decision. 
Opomba: Ta različica povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo je različica, ki je v veljavi v času sprejema odločbe Komisije.
Sixteen patients received 24 epoprostenol dialyses in emergency studies. 
V urgentnih študijah je 16 bolnikov prejelo 24 dializ z epoprostenolom.
Endocrine Disorders 
Bolezni endokrinega sistema
Initially a pack containing solvent for parenteral use must be used. 
Uvodoma je treba uporabiti pakiranje, ki vsebuje vehikel za parenteralno uporabo.
When used in renal dialysis Flolan may be administered as the concentrated solution (a) or in diluted form (b). 
Med uporabo pri ledvični dializi se lahko zdravilo Flolan daje kot koncentrirana raztopina (a) ali v razredčeni obliki (b).
Very common Facial flushing (seen even in the anaesthetised patient) Common 
Žilne bolezni Zelo pogosti zardevanje obraza (opazno celo pri anesteziranih bolnikih)
• build up of fluid in the lungs (pulmonary oedema) 
• kopičenje tekočine v pljučih (pljučni edem),
To dilute the concentrated solution, draw it up into a larger syringe and then attach the sterile filter provided to the syringe. 
Za razredčenje koncentrirane raztopine jo izvlecite v večjo brizgo in nato namestite priloženi sterilni filter.
Flolan is infused continuously through a permanent indwelling central venous catheter via a small, portable infusion pump. 
Zdravilo Flolan se infundira v stalni infuziji po stalnem centralnem venskem katetru z majhno, prenosno infuzijsko črpalko.
Flolan has been successfully used instead of heparin in renal dialysis but in a small proportion of dialyses clotting has developed in the dialysis circuit, requiring termination of dialysis. 
Zdravilo Flolan so pri ledvični dializi uspešno uporabljali namesto heparina, a pri majhnem deležu bolnikov je prišlo do strjevanja v dializnem obtoku, tako da je bilo treba z dializo prenehati.
4.7 Effects on ability to drive and use machines Pulmonary arterial hypertension and its therapeutic management may affect the ability to drive and operate machinery. 
Pljučna arterijska hipertenzija in njeno terapevtsko obvladovanje lahko vplivata na sposobnost vožnje in upravljanja s stroji.
Pulmonary Arterial Hypertension Some patients with pulmonary arterial hypertension have developed pulmonary oedema during doseranging, which may be associated with pulmonary veno-occlusive disease. 
Nekaterim bolnikom s pljučno arterijsko hipertenzijo se je med ugotavljanjem odmerka razvil pljučni edem, ki je lahko povezan s pljučno vensko okluzivno boleznijo.
The amount of sodium present in the powder for solution for infusion equals 2.7 mg approximately per vial. 
Količina natrija v prašku za raztopino za infundiranje je približno 2,7 mg na vialo.
Some medicines may affect how Flolan works, or make it more likely that you'll have side effects. 
Nekatera zdravila lahko vplivajo na delovanje zdravila Flolan ali povečajo verjetnost za pojav neželenih učinkov.
When NSAIDS or other drugs affecting platelet aggregation are used concomitantly, there is the potential for Flolan to increase the risk of bleeding. 
Med sočasno uporabo nesteroidnih protivnetnih zdravil (NSPVZ) ali drugih zdravil, ki vplivajo na agregacijo trombocitov, lahko zdravilo Flolan poveča tveganje za krvavitve.
If the maximum tolerated infusion rate is less than 5 nanograms/kg/min, the long-term infusion should be started at one-half the maximum tolerated infusion rate. 
Če je največja tolerirana hitrost infundiranja manjša od 5 nanogramov/kg/min, je treba dolgotrajno infundiranje začeti s polovično največjo tolerirano hitrostjo infundiranja.
OTHER SPECIAL WARNING(S), IF NECESSARY Use as directed by your physician EXPIRY DATE 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Uporabljajte po zdravnikovih navodilih.
Therefore, this SmPC, labelling and package leaflet may not necessarily represent the current text. 
Tako ta povzetek glavnih značilnosti zdravila, označevanja in navodilo za uporabo morda ne odražajo trenutnega besedila.
The filter must be used once only and then discarded. 
Filter se sme uporabiti samo enkrat in ga je potem treba zavreči.
Major clotting (dialysis permanently suspended, or requiring changing of artificial kidney) occurred in approximately 9% (n=56) of all epoprostenol dialyses and in <1% (n=1) of heparin dialyses in major controlled studies and emergency studies. 
Pomembno strjevanje (trajna prekinitev dialize ali potreba po menjavi umetne ledvice) se je v večjih kontroliranih študijah in urgentnih študijah pojavilo pri približno 9 % (n = 56) vseh dializ z epoprostenolom in pri < 1 % (n = 1) dializ s heparinom.
The primary efficacy endpoint for the study was improvement in the 6MWT. 
Primarni opazovani dogodek v študiji je bilo izboljšanje 6-minutnega testa hoje.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist or nurse. 
Če imate kakšna dodatna vprašanja o uporabi tega zdravila, se obrnite na svojega zdravnika, farmacevta ali medicinsko sestro.
Epoprostenol Sodium, the monosodium salt of epoprostenol, a naturally occurring prostaglandin produced by the intima of blood vessels. 
Natrijev epoprostenolat, mononatrijeva sol epoprostenola, je naraven prostaglandin, ki nastaja v žilni intimi.
Not all pack sizes are available in all markets. 
Na trgu morda ni vseh navedenih pakiranj.
Calculation of infusion rate: 
Izračun hitrosti infundiranja:
The infusion rate may be calculated from the formula given above for renal dialysis. 
Hitrost infundiranja je mogoče izračunati po formuli za ledvično dializo, navedeni zgoraj.
Reconstituted solutions must not be administered over more than 12 hours when they are used at room temperature (between 15°C and 25°C). 
Pripravljene raztopine se ne sme dajati več kot 12 ur, če je uporabljena pri sobni temperaturi (med 15 in 25 °C).
Flolan is used to treat a lung condition called ‘pulmonary arterial hypertension'. 
Zdravilo Flolan se uporablja za zdravljenje pljučne bolezni, imenovane "pljučna arterijska hipertenzija".
When using a ‘cold pouch', the solution can be stored in the pump for up to 24 hours at 2-8oC if necessary. 
Med uporabo "hladne vrečke" je mogoče raztopino shranjevati v črpalki do 24 ur pri temperaturi od 2 do 8 oC, če je treba.
Flolan is a solution for injection made up of powder and solution. 
Zdravilo Flolan je raztopina za injiciranje, pripravljena iz praška in raztopine.
Concentrations commonly used in the treatment pulmonary arterial hypertension are as follows: 
Koncentracije, ki se pogosto uporabljajo pri zdravljenju pljučne arterijske hipertenzije, so:
The filter unit must be used once only and then discarded. 
Filtrirno enoto se sme uporabiti samo enkrat in jo je potem treba zavreči.
Intravenous use Read the package leaflet before use. 
intravenska uporaba Pred uporabo preberite priloženo navodilo!
Flolan comes as a powder in a glass vial. 
Zdravilo Flolan je na voljo kot prašek v stekleni viali.
Bleeding severity worsened during only 1 dialysis day with epoprostenol (N=1/16) whereas severity worsened during 5 dialysis days (N=5/25) and 2 predialysis days (N=2/13) with heparin. 
Izrazitost krvavitev se je z epoprostenolom poslabšala le med 1 dializnim dnevom (n = 1/16), s heparinom pa se je poslabšala med 5 dializnimi dnevi (n = 5/25) in 2 preddializnima dnevoma (n = 2/13).
The amount of sodium present in the solvent for parenteral use equals 53.2 mg approximately per vial. 
Količina natrija v vehiklu za parenteralno uporabo je približno 53,2 mg na vialo.
Flolan contains the active substance epoprostenol which belongs to a group of medicines called prostaglandin, which stops blood from clotting and widens the blood vessels. 
Epoprostenol spada v skupino zdravil, imenovanih prostaglandini; ta zdravila preprečijo strjevanje krvi in razširijo žile.
What Flolan looks like and contents of the pack 
Izgled zdravila Flolan in vsebina pakiranja
Flolan is given by slow infusion (drip) into a vein. 
Zdravilo Flolan se daje s počasno infuzijo (kapalno) v veno.
• Flolan must not be used chronically in patients who develop pulmonary oedema during dose ranging. 
• Zdravila Flolan se ne sme kronično uporabljati pri bolnikih, ki se jim med ugotavljanjem odmerka pojavi pljučni edem.
Flolan must not be used chronically in patients who develop pulmonary edema during dose initiation (see section 4.3). 
Zdravila Flolan se ne sme kronično uporabljati pri bolnikih, ki se jim med uvajanjem odmerka pojavi pljučni edem (glejte poglavje 4.3).
Chronic continuous infusions of epoprostenol in patients with PAH/SSD were studied in a prospective, open, randomised trial of 12 weeks' duration comparing epoprostenol plus conventional therapy (N = 56) to conventional therapy alone (N = 55). 
Kronično stalno infundiranje epoprostenola pri bolnikih s PAH/SSD so raziskali v prospektivnem, odprtem randomiziranem 12-tedenskem preskušanju, ki je primerjalo kombinacijo epoprostenola in konvencionalnega zdravljenja (n = 56) s samim konvencionalnim zdravljenjem (n = 55).
Musculoskeletal and Connective Tissue Disorders Very common Jaw pain Common 
Bolezni mišično-skeletnega sistema in vezivnega tkiva Zelo pogosti bolečina v čeljusti
There are four packs of Flolan available for use in the treatment of pulmonary arterial hypertension, the contents of each pack include: 
Za zdravljenje pljučne arterijske hipertenzije so na voljo štiri pakiranja zdravila Flolan; vsako pakiranje vsebuje:
Long-term infusions should be initiated at 4 nanograms/kg/min less than the maximum tolerated infusion rate determined during short-term dose-ranging. 
Dolgotrajno infundiranje je treba začeti s 4 nanogrami/kg/min manj, kot je največja tolerirana hitrost infundiranja, določena med kratkotrajnim ugotavljanjem odmerka.
Higher circulating doses of epoprostenol (20 nanograms/kg/min) disperse circulating platelet aggregates and increase by up to two fold the cutaneous bleeding time. 
Višji odmerki epoprostenola v obtoku (20 nanogramov/kg/min) ločijo trombocitne agregate v obtoku in do dvakrat podaljšajo kožni čas krvavitve.
You can then be treated using an infusion pump. 
Potem bo mogoče za zdravljenje uporabljati infuzijsko črpalko.